Eli Lilly (LLY) raised $8.94B via multi-series notes maturing 2028–2066 on 2026-05-20. Analysis of balance-sheet impact, leverage and investor considerations.
Eli Lilly (LLY) reports multiple biotech acquisitions and related charges; impact on financials, strategy, and investor risks as of 2025-10-30.
Eli Lilly (LLY) sells Cialis rights in select non-U.S. markets for $180M on 2025-10-30. Investor implications and context for LLY shareholders.
Oct 30, 2025 — Eli Lilly (LLY) reports FDA approvals and positive Phase 3 results, including SURMOUNT‑1's 94% T2D risk reduction in pre‑diabetics.
Eli Lilly (LLY) raises Q3 2025 dividend 15% to $1.50 per share. Coverage of payout implications, buybacks, balance sheet and risks tied to product concentration.
Eli Lilly (LLY) Q3 2025 revenue rose 54% and the company raised full-year guidance. Net income, buybacks, debt and product drivers explained.